当前位置:产品中心 > 抗体 > Biosimilar抗体
TAA
背景介绍

T细胞免疫疗法通常以两类抗原为靶向抗原:私有抗原和公共抗原。公共抗原是指在多个患者中共有的抗原,其中肿瘤相关抗原(TAA)指该抗原在肿瘤细胞中高表达,在健康细胞中也存在但表达水平较低的抗原。

目前有许多肿瘤相关抗原及肿瘤特异性抗原被发现,以TAA为目标的靶向治疗是癌症治疗的重要途径。市场上已经有几种依赖此机制的癌症免疫治疗药物,他们在临床上非常有效。开发针对TAA的药物仍然是一个非常活跃的研究领域。目前有非常多的针对不同种类的肿瘤类型的靶向药物正在进行临床前或者临床检测。针对TAA的抗体不仅可以通过ADCC效应直接杀死肿瘤细胞,也可以作为诊断标记物或者创新性的增加传统癌症疗法的靶向性。


TAA-2.png

TAA现货清单
靶点 产品货号 产品名称
CEACAM
GM-30164AB
Anti-H_CEACAM1(CD66a) hIgG4 Antibody(MK-6018)
CEACAM
GM-28531AB
Anti-CEA hIgG1 Antibody(Cibisatamab)
CEACAM
GM-51007AB
Anti-CEACAM7 hIgG4 Antibody(2869)
CEACAM
GM-30166AB
Anti-H_CEACAM6(CD66c) hIgG1 Antibody(Tinurilimab)
SEZ6
GM-86544AB
Anti-SEZ6 hIgG1 Antibody(ABBV-011)
IL13RA2
GM-86015AB
Anti-IL13RA2 hIgG1 Antibody(61H8C1)
TSPAN8
GM-82623AB
Anti-TSPAN8 mIgG2b Antibody(Ts29.2)
CD38
GM-27202AB
Anti-CD38 hIgG1 Antibody(Daratumumab)
CDH17
GM-75321AB
Anti-CDH17 hIgG1 Antibody(VHHl-28BB)
CDH17
GM-52672AB
Anti-CDH17 hIgG1 Antibody(BI-905711)
F3(CD142)
GM-28928AB
Anti-H_F3(CD142) hIgG1 Antibody(Tisotumab)
CA9(CAIX)
GM-27130AB
Anti-H_CAIX hIgG1 Antibody(girentuximab)
ALPPL2 ALPP
GM-58773AB
Anti-ALPPL2 mIgG2a antibody(SGN-ALPV)
ALPPL2 ALPP
GM-58774AB
Anti-ALPPL2 hIgG1 antibody(SGN-ALPV)
ALPPL2 ALPP
GM-86291MAB
Anti-H_ALPPL2 hIgG1 Reference Antibody(h12F3)
PTK7
GM-56186AB
Anti-PTK7 hIgG1 Antibody(Cofetuzumab)
CD4
GM-28752AB
Anti-H_CD4 hIgG1 Antibody(Tregalizumab)
TM4SF1
GM-59885AB
Anti-TM4SF1 hIgG1 Antibody(hAGX-A01H1L10&8G4)
TM4SF1
GM-59881AB
Anti-TM4SF1 hIgG1 Antibody(hAGX-A07H2L5)
LY6G6D
GM-58917AB
Anti-LY6G6D hIgG1 Antibody(20A12 .QNTv12)
FAP
GM-30156AB
Anti-H_FAP hIgG1 Antibody(Simlukafusp)
NFRSF8(CD30)
GM-28856AB
Anti-H_TNFRSF8(CD30) hIgG1 Antibody(Brentuximab)
GPA33
GM-52271AB
Anti-GPA33 hIgG1 Antibody(DART-2)
GPA33
GM-50417AB
Anti-H_GPA33 hIgG1 Antibody(A2)
DLL
GM-51820AB
Anti-DLL4 hIgG1 Antibody(MLCK-2(ABL-001)
DLL
GM-51815AB
Anti-DLL4 hIgG2 Antibody(Navicixizumab)
DLL
GM-26560AB
Anti-H_DLL3 hIgG1 Antibody(Rovalpituzumab)
MUC1
GM-28930AB
Anti-H_MUC1(CD227)hIgG1 Antibody(Clivatuzumab)
CD19
GM-28777AB
Anti-H_CD19 hIgG1/hIgG2 Antibody(Tafasitamab)
CD22(SIGLEC2)
GM-31561AB
Anti-H_CD22 hIgG1 Antibody(Pinatuzumab)
GPC3
GM-28751AB
Anti-GPC3 hIgG1 Antibody(Codrituzumab)
CLEC12A
GM-52592AB
Anti-CLEC12A hIgG1 Antibody(H6e7)
BCMA
GM-52396AB
Anti-BCMA hIgG1 Antibody(Belantamab)
BCMA
GM-49486AB
Anti-BCMA hIgG1 Antibody(SEA-BCMA)
BCMA
GM-49476AB
Anti-BCMA hIgG4 Antibody(BCMB69)
CDH6
GM-46607AB
Anti-H_CDH6 hIgG1 Antibody(H01L02)
FOLR1
GM-27354AB
Anti-FOLR1 hIgG1 Antibody(Mirvetuximab)
FOLR1
GM-86372MAB
Anti-H_FOLR1 hIgG1 Reference Antibody(Mirvebio)
FOLH1(PSMA)
GM-27353AB
Anti-FOLH1(PSMA) hIgG1 Antibody(Rosopatamab)
SLC34A2
GM-26828AB
Anti-SLC34A2 hIgG1 Antibody(XMT-1536)
GUCY2C
GM-28860AB
Anti-H_GUCY2C hIgG1 Antibody(Indusatumab)
TROP2
GM-26561AB
Anti-H_TROP2 hIgG1 Antibody(datopotamab)
AMHR2
GM-27802AB
Anti-AMHR2 hIgG1 Antibody(Murlentamab)
CD123(IL3RA)
GM-27123AB
Anti-H_CD123 hIgG2 Antibody(Talacotuzumab)
MSLN
GM-24027AB
Anti-H_MSLN hIgG1 Antibody(Amatuximab)
CDH3
GM-46573AB
Anti-H_CDH3 hIgG1 Antibody
NECTIN4
GM-23369AB
Anti-H_Nectin4 hIgG1 Antibody (Enfortumab)
CEACAM8
GM-49164AB
Anti-CEACAM8 hIgG1 Antibody(Besilesomab)
产品中心 > 抗体 > Biosimilar抗体

TAA
TAA现货清单
靶点 产品货号 产品名称
CEACAM
GM-30164AB
Anti-H_CEACAM1(CD66a) hIgG4 Antibody(MK-6018)
CEACAM
GM-28531AB
Anti-CEA hIgG1 Antibody(Cibisatamab)
CEACAM
GM-51007AB
Anti-CEACAM7 hIgG4 Antibody(2869)
CEACAM
GM-30166AB
Anti-H_CEACAM6(CD66c) hIgG1 Antibody(Tinurilimab)
SEZ6
GM-86544AB
Anti-SEZ6 hIgG1 Antibody(ABBV-011)
IL13RA2
GM-86015AB
Anti-IL13RA2 hIgG1 Antibody(61H8C1)
TSPAN8
GM-82623AB
Anti-TSPAN8 mIgG2b Antibody(Ts29.2)
CD38
GM-27202AB
Anti-CD38 hIgG1 Antibody(Daratumumab)
CDH17
GM-75321AB
Anti-CDH17 hIgG1 Antibody(VHHl-28BB)
CDH17
GM-52672AB
Anti-CDH17 hIgG1 Antibody(BI-905711)
F3(CD142)
GM-28928AB
Anti-H_F3(CD142) hIgG1 Antibody(Tisotumab)
CA9(CAIX)
GM-27130AB
Anti-H_CAIX hIgG1 Antibody(girentuximab)
ALPPL2 ALPP
GM-58773AB
Anti-ALPPL2 mIgG2a antibody(SGN-ALPV)
ALPPL2 ALPP
GM-58774AB
Anti-ALPPL2 hIgG1 antibody(SGN-ALPV)
ALPPL2 ALPP
GM-86291MAB
Anti-H_ALPPL2 hIgG1 Reference Antibody(h12F3)
PTK7
GM-56186AB
Anti-PTK7 hIgG1 Antibody(Cofetuzumab)
CD4
GM-28752AB
Anti-H_CD4 hIgG1 Antibody(Tregalizumab)
TM4SF1
GM-59885AB
Anti-TM4SF1 hIgG1 Antibody(hAGX-A01H1L10&8G4)
TM4SF1
GM-59881AB
Anti-TM4SF1 hIgG1 Antibody(hAGX-A07H2L5)
LY6G6D
GM-58917AB
Anti-LY6G6D hIgG1 Antibody(20A12 .QNTv12)
FAP
GM-30156AB
Anti-H_FAP hIgG1 Antibody(Simlukafusp)
NFRSF8(CD30)
GM-28856AB
Anti-H_TNFRSF8(CD30) hIgG1 Antibody(Brentuximab)
GPA33
GM-52271AB
Anti-GPA33 hIgG1 Antibody(DART-2)
GPA33
GM-50417AB
Anti-H_GPA33 hIgG1 Antibody(A2)
DLL
GM-51820AB
Anti-DLL4 hIgG1 Antibody(MLCK-2(ABL-001)
DLL
GM-51815AB
Anti-DLL4 hIgG2 Antibody(Navicixizumab)
DLL
GM-26560AB
Anti-H_DLL3 hIgG1 Antibody(Rovalpituzumab)
MUC1
GM-28930AB
Anti-H_MUC1(CD227)hIgG1 Antibody(Clivatuzumab)
CD19
GM-28777AB
Anti-H_CD19 hIgG1/hIgG2 Antibody(Tafasitamab)
CD22(SIGLEC2)
GM-31561AB
Anti-H_CD22 hIgG1 Antibody(Pinatuzumab)
GPC3
GM-28751AB
Anti-GPC3 hIgG1 Antibody(Codrituzumab)
CLEC12A
GM-52592AB
Anti-CLEC12A hIgG1 Antibody(H6e7)
BCMA
GM-52396AB
Anti-BCMA hIgG1 Antibody(Belantamab)
BCMA
GM-49486AB
Anti-BCMA hIgG1 Antibody(SEA-BCMA)
BCMA
GM-49476AB
Anti-BCMA hIgG4 Antibody(BCMB69)
CDH6
GM-46607AB
Anti-H_CDH6 hIgG1 Antibody(H01L02)
FOLR1
GM-27354AB
Anti-FOLR1 hIgG1 Antibody(Mirvetuximab)
FOLR1
GM-86372MAB
Anti-H_FOLR1 hIgG1 Reference Antibody(Mirvebio)
FOLH1(PSMA)
GM-27353AB
Anti-FOLH1(PSMA) hIgG1 Antibody(Rosopatamab)
SLC34A2
GM-26828AB
Anti-SLC34A2 hIgG1 Antibody(XMT-1536)
GUCY2C
GM-28860AB
Anti-H_GUCY2C hIgG1 Antibody(Indusatumab)
TROP2
GM-26561AB
Anti-H_TROP2 hIgG1 Antibody(datopotamab)
AMHR2
GM-27802AB
Anti-AMHR2 hIgG1 Antibody(Murlentamab)
CD123(IL3RA)
GM-27123AB
Anti-H_CD123 hIgG2 Antibody(Talacotuzumab)
MSLN
GM-24027AB
Anti-H_MSLN hIgG1 Antibody(Amatuximab)
CDH3
GM-46573AB
Anti-H_CDH3 hIgG1 Antibody
NECTIN4
GM-23369AB
Anti-H_Nectin4 hIgG1 Antibody (Enfortumab)
CEACAM8
GM-49164AB
Anti-CEACAM8 hIgG1 Antibody(Besilesomab)
背景介绍

T细胞免疫疗法通常以两类抗原为靶向抗原:私有抗原和公共抗原。公共抗原是指在多个患者中共有的抗原,其中肿瘤相关抗原(TAA)指该抗原在肿瘤细胞中高表达,在健康细胞中也存在但表达水平较低的抗原。

目前有许多肿瘤相关抗原及肿瘤特异性抗原被发现,以TAA为目标的靶向治疗是癌症治疗的重要途径。市场上已经有几种依赖此机制的癌症免疫治疗药物,他们在临床上非常有效。开发针对TAA的药物仍然是一个非常活跃的研究领域。目前有非常多的针对不同种类的肿瘤类型的靶向药物正在进行临床前或者临床检测。针对TAA的抗体不仅可以通过ADCC效应直接杀死肿瘤细胞,也可以作为诊断标记物或者创新性的增加传统癌症疗法的靶向性。


TAA-2.png

Tel: 400-627-9288
留言咨询
重置
提交
客服
微信
电话
留言
留言咨询
重置
提交